Biochemical Engineering Special Interest Group
biological engineering professionals
17 February 2017

British investment firm Arix Bioscience hits £100M IPO target

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the new funds to use in investments across as many as 15 early-stage biotechs. The firm has some key names coming out of its investments, including Woodford Investment Management, UCB and Takeda’s venture arm, as well as links to U.K. life sciences entrepreneur Sir Chris Evans, founder of Excalibur Group and Arix’s deputy chairman. It raised £50 million last year and invested in five biotech companies. Source: FierceBiotech 17/2/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).